Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 57Breast 14Lymphoid 4Gynecologic 4Sarcoma 2Other solid neoplasm 1Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Adenocarcinoma 1

Interventions

Cisplatin 619pembrolizumab 323Radiotherapy 319Cetuximab 274Docetaxel 220Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 74Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 48Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 43tislelizumab 42Standard of Care 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triptorelin Pamoate × Head & Neck × Clear all
NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡